Paper27487144
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
Wadosky KM and 1 other. Oncotarget, 2016. Cited by 142 papers, by iCite.
Cite this record
ConductScience Library. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Papers, record 27487144. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27487144
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Androgen Antagonists | Major topic |
| Antineoplastic Agents, Hormonal | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Prostatic Neoplasms, Castration-Resistant | Major topic |
| Receptors, Androgen | Major topic |
| Animals | |
| Humans | |
| Kallikreins | |
| Male | |
| Mutation | |
| Neoplasm Staging | |
| Phosphorylation | |
| Prostate-Specific Antigen | |
| Risk Factors | |
| Signal Transduction | |
| Treatment Outcome |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016056 | NCI NIH HHS | United States | P30CA016056 | PubMed and NIH | NIH RePORTER |
| R21 CA181152 | NCI NIH HHS | United States | R21CA181152 | PubMed and NIH | NIH RePORTER |
| R21 CA183892 | NCI NIH HHS | United States | R21CA183892 | PubMed and NIH | NIH RePORTER |
References183
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10797498 | Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. | Prostate | 2000 | https://conductscience.org/library/papers/10797498 | PubMed |
| 2 | 14976540 | Gleason grading and prognostic factors in carcinoma of the prostate. | Mod Pathol | 2004 | https://conductscience.org/library/papers/14976540 | PubMed |
| 3 | 18182665 | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18182665 | PubMed |
| 4 | 26000489 | Integrative clinical genomics of advanced prostate cancer. | Cell | 2015 | https://conductscience.org/library/papers/26000489 | PubMed |
| 5 | 10569618 | Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. | J Urol | 1999 | https://conductscience.org/library/papers/10569618 | PubMed |
| 6 | 23228172 | Abiraterone in metastatic prostate cancer without previous chemotherapy. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23228172 | PubMed |
| 7 | 22872761 | Regulation of the androgen receptor by post-translational modifications. | J Endocrinol | 2012 | https://conductscience.org/library/papers/22872761 | PubMed |
| 8 | 18511414 | Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. | J Biol Chem | 2008 | https://conductscience.org/library/papers/18511414 | PubMed |
| 9 | 18834855 | Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. | Biochem Biophys Res Commun | 2008 | https://conductscience.org/library/papers/18834855 | PubMed |
| 10 | 20842666 | Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. | Prostate | 2011 | https://conductscience.org/library/papers/20842666 | PubMed |
| 11 | 3353726 | Molecular cloning of human and rat complementary DNA encoding androgen receptors. | Science | 1988 | https://conductscience.org/library/papers/3353726 | PubMed |
| 12 | 21446008 | A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. | Prostate | 2011 | https://conductscience.org/library/papers/21446008 | PubMed |
| 13 | 20141676 | NCCN clinical practice guidelines in oncology: prostate cancer. | J Natl Compr Canc Netw | 2010 | https://conductscience.org/library/papers/20141676 | PubMed |
| 14 | 17949893 | An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. | Eur Urol | 2008 | https://conductscience.org/library/papers/17949893 | PubMed |
| 15 | 20124400 | Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. | CA Cancer J Clin | 2010 | https://conductscience.org/library/papers/20124400 | PubMed |
| 16 | 23147995 | miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23147995 | PubMed |
| 17 | 25512207 | Targeting heat shock proteins in metastatic castration-resistant prostate cancer. | Nat Rev Urol | 2015 | https://conductscience.org/library/papers/25512207 | PubMed |
| 18 | 22266859 | Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. | Oncogene | 2012 | https://conductscience.org/library/papers/22266859 | PubMed |
| 19 | 17557956 | Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17557956 | PubMed |
| 20 | 15046683 | Ten-year survival in patients with metastatic prostate cancer. | Clin Prostate Cancer | 2003 | https://conductscience.org/library/papers/15046683 | PubMed |
Cited by107
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 142 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941926 | Potential Molecular Links Between Triclosan Exposure and Prostate Cancer: An Integrative Computational Analysis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941926 | PubMed |
| 42662529 | Asymmetric cross-reactivity of nuclear receptors reveals an evolutionary buffer between estrogen and androgen signaling. | iScience | 2026 | https://conductscience.org/library/papers/42662529 | PubMed |
| 42209670 | Single-cell and spatial RNA sequencing in prostate cancer. | Nat Rev Urol | 2026 | https://conductscience.org/library/papers/42209670 | PubMed |
| 42092921 | Testosterone and cancers: biological functions, molecular mechanisms and therapy. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42092921 | PubMed |
| 42012624 | LMNB2 promotes prostate cancer progression and epithelial-mesenchymal transition via the Wnt/β-catenin pathway. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42012624 | PubMed |
| 41939207 | Liposomal Delivery Systems for Improved Delivery of Docetaxel Against Prostate Cancer. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/41939207 | PubMed |
| 41898445 | Anabolic-Androgenic Steroids Revisited: Structural Biology, Receptor Signaling, and Mechanisms of Anabolic-Androgenic Dissociation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41898445 | PubMed |
| 41303628 | Targeting Prostate Cancer Cells Using Anti-Sortilin and Anti-Syndecan-1 Antibody Drug Conjugates. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41303628 | PubMed |
| 41228300 | Pharmacokinetics and Pharmacodynamics of Perfluorooctane Sulfonate (PFOS) and Its Role in the Development and Progression of Prostate, Ovarian and Breast Cancers. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228300 | PubMed |
| 41176761 | Association of Germline Single Nucleotide Polymorphisms in Steroid Hormone Metabolism Pathway With Androgen Deprivation Therapy Prognosis of Prostate Cancer in Chinese Population. | Cancer Med | 2025 | https://conductscience.org/library/papers/41176761 | PubMed |
| 40963603 | Integrative single-cell and machine learning analysis predicts lactylation-driven therapy resistance in prostate cancer: a molecular docking and experiments-validated framework for treatment optimization. | Front Immunol | 2025 | https://conductscience.org/library/papers/40963603 | PubMed |
| 40868127 | GSTM5 as a Potential Biomarker for Treatment Resistance in Prostate Cancer. | Biomedicines | 2025 | https://conductscience.org/library/papers/40868127 | PubMed |
| 40832004 | PROTAC technology for prostate cancer treatment. | Acta Mater Med | 2025 | https://conductscience.org/library/papers/40832004 | PubMed |
| 40776758 | Cancer‑associated fibroblasts in human malignancies, with a particular emphasis on sarcomas (Review). | Int J Oncol | 2025 | https://conductscience.org/library/papers/40776758 | PubMed |
| 40520577 | Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement. | Mol Ther Oncol | 2025 | https://conductscience.org/library/papers/40520577 | PubMed |
| 40391771 | Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells. | Oncotarget | 2025 | https://conductscience.org/library/papers/40391771 | PubMed |
| 40303463 | Combined Transcriptomic and Epitranscriptomic Profiling Identifies THBS1 as A Regulator of Enzalutamide Resistance in Prostate Cancer. | Cancer Heterog Plast | 2025 | https://conductscience.org/library/papers/40303463 | PubMed |
| 39857976 | Prostate Cancer: A Journey Through Its History and Recent Developments. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/39857976 | PubMed |
| 39351434 | Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies. | Explor Target Antitumor Ther | 2024 | https://conductscience.org/library/papers/39351434 | PubMed |
| 39327674 | Selective killing of castration-resistant prostate cancer cells by formycin A via the ATF4-CHOP axis. | Cancer Sci | 2024 | https://conductscience.org/library/papers/39327674 | PubMed |
Genes39
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27487144
GET https://conductscience.org/api/papers/v1/27487144/references?page=2